Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy’s output with the perspective offered by EAACI’s partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.

1. Agache I, Akdis CA, Chivato T, et al. EAACI white paper on research, innovation and quality care [Accessed 2019 Febr 14]. Available from: www.eaaci.org/resources/books/white-paper.html.

2. Bion V, Lockett GA, Soto-Ramírez N, et al. Evaluating the efficacy of breastfeeding guidelines on long-term outcomes for allergic disease. Allergy. 2016;71(5):661–670. doi: 10.1111/all.12833.

3. Victora CG, Bahl R, Barros A, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet. 2016;387:475–490. doi: 10.1016/S0140-6736(15)01024-7.

4. Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy. 2014;69(8):992–1007. doi: 10.1111/all.12423.

5. Muraro A, Agache I, Clark A, et al.; European Academy of Allergy and Clinical Immunology. EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community. Allergy. 2014;69(8):1046–1057. doi: 10.1111/all.12441.

6. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020 [Accessed 2019 Febr 25]. Available from: www.who.int.

7. Branca F, Lartey A, Oenema S, et al. Transforming the food system to fight noncommunicable diseases. BMJ. 2019;364:l296. doi: 10.1136/bmj.l296.

8. Willett W, Rockström J, Loken B, et al. Food in the anthropocene: the EAT-lancet commission on healthy diets from sustainable food systems. Lancet. 2019;393(10170):447-492. doi: 10.1016/S0140-6736(18)31788-4.

9. Zimmer J, Vieths S, Kaul S. Standardization and regulation of allergen products in the European Union. Curr Allergy Asthma Rep. 2016;16(3):21. doi: 10.1007/s11882-016-0599-4.

10. Bonertz A, Roberts G, Slater JE, et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: an analysis from the EAACI AIT guidelines project. Allergy. 2018;73(4):816–826. doi: 10.1111/all.13357.

11. Bieber T, Vieths S, Broich K. New opportunities and challenges in the assessment of drugs for atopic diseases. Allergy. 2016;71(12):1662–1665. doi: 10.1111/all.13063.

12. Kaul S, Zimmer J, Dehus O, et al. Standardization of allergen products: 3. Validation of candidate European Pharmacopoeia standard methods for quantification of major birch allergen Bet v 1. Allergy. 2016;71(10):1414–1424. doi: 10.1111/all.12898.

13. Zimmer J, Bonertz A, Vieths S. Quality requirements for allergen extracts and allergoids for allergen immunotherapy. Allergol Immunopathol (Madr). 2017;45(Suppl 1):4–11. doi: 10.1016/j.aller.2017.09.002.

14. De Monchy JG, Demoly P, Akdis CA, et al. Allergology in Europe, the blueprint. Allergy 2013;68(10):1211–1218. doi: 10.1111/all.12225.

15. Gerth van Wijk R, Eguiluz-Gracia I, Gayraud J, et al. The roadmap for allergology in Europe: The subspecialty of allergology as “stopover” on the way to a full specialty. An EAACI position statement. Allergy. 2018;73(3):540–548. doi: 10.1111/all.13321.

16. Katsaounou P, Odemyr M, Spranger O, et al. Still fighting for breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res. 2018;4(4):00076–2018. doi: 10.1183/23120541.00076-2018.

17. Honkoop PJ, Simpson A, Bonini M, et al. MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study. BMJ Open. 2017;7:e013935. doi: 10.1136/bmjopen-2016-013935.

18. Sanyal S, Rochereau T, Maesano C, et al. Long-term effect of outdoor air pollution on mortality and morbidity: a 12-year follow-up study for metropolitan France. Int J Environ Res Public Health. 2018;15(11):2487. doi: 10.3390/ijerph15112487.

19. D’Amato G, Annesi-Maesano I, Cecchi L, D’Amato M. Latest news on relationship between thunderstorms and respiratory allergy, severe asthma, and deaths for asthma. Allergy. 2019;74(1):9–11. doi: 10.1111/all.13616.

20. Bousquet J, Anto JM, Akdis M, et al. Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: mechanisms of the development of allergy; EU FP7-CP-IP; project No: 261357; 2010–2015. Allergy. 2016;71(11):1513–1525. doi: 10.1111/all.12880.

21. Walker SM, Akdis C, Dahlen SE, et al. Building the investment case for asthma R&D: the European asthma research and innovation partnership argument. Clin Exp Allergy. 2016;46(9):1136–1138. doi: 10.1111/cea.12779.

22. Cecchi L, D’Amato G, Annesi-Maesano I. External exposome and allergic respiratory and skin diseases. J Allergy Clin Immunol. 2018;141(3):846–857. doi: 10.1016/j.jaci.2018.01.016.

23. Agache I, Miller R, Gern JE, et al. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma. Allergy. 2019;74(3):449–463. doi: 10.1111/all.13690.

24. Migliori GB, Bel E, Joos G, et al. The European Respiratory Society evaluates its 2013–2018 strategic plan implementation. Eur Respir J. 2016;47(3):693–698. doi: 10.1183/13993003.02110-2015.

25. Soriano JB, Paton J, Martin Burrieza F, et al. The ERS research agency: the beginning. Eur Respir J. 2016;47(4):1017–1023. doi: 10.1183/13993003.02109-2015.

26. Maio S, Baldacci S, Bresciani M, et al. RItA: the Italian severe/uncontrolled asthma registry. Allergy. 2018;73(3):683–695. doi: 10.1111/all.13342.

27. Liu NM, van Aalderen W, Carlsen K, et al. Severe Paediatric Asthma Collaborative in Europe (SPACE): protocol for a European registry. Breathe. 2018;14(2):93–98. doi: 10.1183/20734735.002018.

28. Kercsmar CM, Sorkness CA, Calatroni A, et al. A computerized decision support tool to implement asthma guidelines for children and adolescents. J Allergy Clin Immunol. 2019;143(5):1760–1768. doi: 10.1016/j.jaci.2018.10.060.

29. Papadopoulos NG, Custovic A, Cabana MD, et al. Pediatric asthma: an unmet need for more effective, focused treatments. Pediatr Allergy Immunol. 2019;30(1):7–16. doi: 10.1111/pai.12990.

30. Vishneva E, Namazova-Baranova LV, Alekseeva A, et al. The pediatric asthma patient registry in implementation of long term follow up. Value Health. 2015;18(7):A693.

31. Leiding JW, Ballow M. Precision medicine in the treatment of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. 2018;18(2):159–166. doi: 10.1097/ACI.0000000000000431.

32. Odnoletkova I, Kindle G, Quinti I, et al. Plasma Protein Therapeutics Association (PPTA) Taskforce. The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet J Rare Dis. 2018;13(1):201. doi: 10.1186/s13023-018-0941-0.

33. To T, Cruz AA, Viegi G, et al. A strategy for measuring health outcomes and evaluating impacts of interventions on asthma and COPD-common chronic respiratory diseases in Global Alliance against Chronic Respiratory Diseases (GARD) countries. J Thorac Dis. 2018;10(8):5170–5177. doi: 10.21037/jtd.2018.08.100.

34. Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis — A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297–1305. doi: 10.1111/all.13162.

35. Valiulis A, Bousquet J, Veryga A, et al. Vilnius declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases. Clin Transl Allergy. 2019;9:7. doi: 10.1186/s13601-019-0242-2.

36. Butler D. Translational research: crossing the valley of death. Nature. 2008;453:840–842. doi: 10.1038/453840a.

37. Woolf SH. The meaning of translational research and why it matters. JAMA 2008;299:211–213. doi: 10.1001/jama.2007.26.

38. Bender BG. A bootstrap approach to implementation science. Ann Allergy Asthma Immunol. 2016;117:213–216. doi: 10.1016/j.anai.2016.07.007.

39. Cunningham S, Pinnock H. Implementation science takes baby steps in infants with bronchiolitis. Thorax 2018;73(7):599–600. doi: 10.1136/thoraxjnl-2017-211455.

40. Colborn KL, Helmkamp L, Bender BG, et al. Colorado asthma toolkit implementation improves some process measures of asthma care. J Am Board Fam Med. 2019;32(1):37–49. doi: 10.3122/jabfm.2019.01.180155.

41. Crable EL, Biancarelli D, Walkey AJ, et al. Standardizing an approach to the evaluation of implementation science proposals. Implement Sci. 2018;13(1):71. doi: 10.1186/s13012-018-0770-5.

42. Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation Studies (StaRI) Statement. BMJ. 2017;356:i6795. doi: 10.1136/bmj.i6795.

43. Bonini S, Bonini M. Biosimilars and drug development in immunologic diseases. J Allergy Clin Immunol. 2017;139:1461–1464. doi: 10.1016/j.jaci.2017.03.008.

44. Rasi G, Bonini S. Innovative medicines; new regulatory procedures for the third millennium. Expert Opin Biol Ther. 2015;15:5–8. doi: 10.1517/14712598.2015.1026322.

45. Barnes PJ, Bonini S, Seeger W, et al. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45(5):1197–1207. doi: 10.1183/09031936.00007915.

46. Bonini S, Eichler HG, Wathion N, Rasi G. Transparency and the European Medicines Agency. Sharing of clinical trial data. N Engl J Med. 2014;371:2552–2555. doi: 10.1056/NEJMp1409464.

47. Palomares O, Crameri R, Rhyner C. The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases. Allergy. 2014;69(12):1588–1601. doi: 10.1111/all.12533.

48. Diver S, Brightling CE. Big asthma data: getting bigger and more beautiful? Thorax. 2018;73(4):311–312. doi: 10.1136/thoraxjnl-2017-211148.

49. Pandey G, Pandey OP, Rogers AJ, et al. A nasal brush-based classifier of asthma identified by machine learning analysis of nasal RNA sequence data. Sci Rep. 2018;8(1):8826. doi: 10.1038/s41598-018-27189-4.

50. Ross MK, Yoon J, van der Schaar A, van der Schaar M. Discovering pediatric asthma phenotypes on the basis of response to controller medication using machine learning. Ann Am Thorac Soc. 2018;15(1):49–58. doi: 10.1513/AnnalsATS.201702-101OC.

51. Ghosh D, Bernstein JA, Khurana Hershey GK, et al. Leveraging Multilayered “Omics” Data for Atopic Dermatitis: A Road Map to Precision Medicine. Front Immunol. 2018;9:2727. doi: 10.3389/fimmu.2018.02727.

52. Bieber T, Akdis C, Lauener R, et al. Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicine. Allergy. 2016;71(5):588–592. doi: 10.1111/all.12857.

53. Nieuwenhuis MA, Siedlinski M, van den Berge M, et al. Combining genome-wide association study and lung eQTL analysis provides evidence for novel genes associated with asthma. Allergy. 2016;71(12):1712–1720. doi: 10.1111/all.12990.

54. Loureiro CC, Oliveira AS, Santos M, et al. Urinary metabolomic profiling of asthmatics can be related to clinical characteristics. Allergy. 2016;71(9):1362–1365. doi: 10.1111/all.12935.

55. Obeso D, Mera-Berriatua L, Rodríguez-Coira J, et al. Multiomics analysis points to altered platelet functions in severe foodassociated respiratory allergy. Allergy. 2018;73(11):2137–2149. doi: 10.1111/all.13563.

56. Villaseñor A, Rosace D, Obeso D, et al. Allergic asthma: an overview of metabolomic strategies leading to the identification of biomarkers in the field. Clin Exp Allergy. 2017;47(4):442–456. doi: 10.1111/cea.12902.

57. Rodrigo-Muñoz JM, Cañas JA, Sastre B, et al. Asthma diagnosis using integrated analysis of eosinophil microRNAs. Allergy. 2019;74(3):507–517. doi: 10.1111/all.13570.

58. Doña I, Jurado-Escobar R, Perkins JR, et al. Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria. Allergy. 2019;74(6):1135-1144. doi: 10.1111/all.13725.

59. Segura-Bedmar I, Colon-Ruiz C, Tejedor-Alonso MA, Moro-Moro M. Predicting of anaphylaxis in big data EMR by exploring machine learning approaches. J Biomed Inform. 2018;87:50–59. doi: 10.1016/j.jbi.2018.09.012.

60. Bousquet J, Agache I, Anto JM, et al. Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy. 2017;72(8):1261–1266. doi: 10.1111/all.13137.

61. Bonini M. Electronic health (e-Health): emerging role in asthma. Curr Opin Pulm Med. 2017;23(1):21–26. doi: 10.1097/MCP.0000000000000336.

62. Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and highlights in biomarkers in allergic diseases and asthma. Allergy. 2018;73(12):2290–3230. doi: 10.1111/all.13628.

63. Agache I, Rogozea L. Endotypes in allergic diseases. Curr Opin Allergy Clin Immunol. 2018;18(3):177–183. doi: 10.1097/ACI.0000000000000434.

64. Agache I, Strasser DS, Pierlot GM, et al. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. J Allergy Clin Immunol. 2018;141(1):442–445. doi: 10.1016/j.jaci.2017.08.027.

65. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347–1358. doi: 10.1016/j.jaci.2016.03.010.

66. Finkelstein J, Wood J. Predicting asthma exacerbations using artificial intelligence. Stud Health Technol Inform. 2013;190:56–58.

67. Finkelstein J, Jeong IC. Machine learning approaches to personalize early prediction of asthma exacerbations. Ann N Y Acad Sci. 2017;1387(1):153–165. doi: 10.1111/nyas.13218.

68. Sukumar SR, Natarajan R, Ferrell RK. Quality of big data in health care. Int J Health Care Qual Assur. 2015;28(6):621–634. doi: 10.1108/IJHCQA-07-2014-0080.

69. Hordern V. Data protection compliance in the age of digital health. Eur J Health Law. 2016;23(3):248–264. doi: 10.1163/15718093-12341393.

70. Rumbold JM, Pierscionek B. The effect of the general data protection regulation on medical research. J Med Internet Res. 2017;19(2):e47. doi: 10.2196/jmir.7108.

71. Garcia-Larsen V, Del Giacco SR, Moreira A, et al. Asthma and dietary intake: an overview of systematic reviews. Allergy 2016;71(4):433–442. doi: 10.1111/all.12800.

72. Paciência I, Cavaleiro Rufo J, Silva D, et al. Exposure to indoor endocrine disrupting chemicals and childhood asthma and obesity. Allergy. 2019;74(7):1277-1291. doi: 10.1111/all.13740.

73. Steckling N, Gotti A, Bose-O’Reilly S, et al. Biomarkers of exposure in environment-wide association studies Opportunities to decode the exposome using human biomonitoring data. Environ Res. 2018;164:597–624. doi: 10.1016/j.envres.2018.02.041.

74. Krautenbacher N, Flach N, Böck A, et al. A strategy for high-dimensional multivariable analysis classifies childhood asthma phenotypes from genetic, immunological and environmental factors. Allergy. 2019;74(7):1364-1373. doi: 10.1111/all.13745.

75. Venter C, Meyer RW, Nwaru BI, et al. EAACI position paper: influence of dietary fatty acids on asthma, food allergy and atopic dermatitis. Allergy. 2019;74(8):1429-1444. doi: 10.1111/all.13764.

76. Wickens K, Barthow C, Mitchell EA, et al. Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years. Pediatr Allergy Immunol. 2018;29(8):808–814. doi: 10.1111/pai.12982.

77. Lerner H, Berg C. The concept of health in One Health and some practical implications for research and education: what is One Health? Infect Ecol Epidemiol. 2015;5:25300. doi: 10.3402/iee.v5.25300.

78. Xie T, Liu W, Anderson BD, et al. A system dynamics approach to understanding the One Health concept. PLoS ONE. 2017;12(9):e0184430. doi: 10.1371/journal.pone.0184430.

79. Khan SJ, Dharmage SC, Matheson MC, Gurrin LC. Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data. Allergy. 2018;73(1):17–28. doi: 10.1111/all.13228.

80. Lockett GA, Soto-Ramírez N, Ray MA, et al. Association of sea son of birth with DNA methylation and allergic disease. Allergy. 2016;71(9):1314–1324. doi: 10.1111/all.12882.

81. Savage JH, Lee-Sarwar KA, Sordillo J, et al. A prospective microbiome-wide association study of food sensitization and food allergy in early childhood. Allergy. 2018;73(1):145–152. doi: 10.1111/all.13232.

82. Jatzlauk G, Bartel S, Heine H, et al. Influences of environmental bacteria and their metabolites on allergies, asthma, and host microbiota. Allergy. 2017;72(12):1859–1867. doi: 10.1111/all.13220.

83. Birzele LT, Depner M, Ege MJ, et al. Environmental and mucosal microbiota and their role in childhood asthma. Allergy. 2017;72(1):109–119. doi: 10.1111/all.13002.

84. Muir AB, Benitez AJ, Dods K, et al. Microbiome and its impact on gastrointestinal atopy. Allergy. 2016;71(9):1256–1263. doi: 10.1111/all.12943.

85. Lau S, Matricardi PM, Wahn U, et al. Allergy and atopy from infancy to adulthood: messages from the German birth cohort MAS. Ann Allergy Asthma Immunol. 2019;122(1):25–32. doi: 10.1016/j.anai.2018.05.012.

86. Thacher JD, Gruzieva O, Pershagen G, et al. Parental smoking and development of allergic sensitization from birth to adolescence. Allergy. 2016;71(2):239–248. doi: 10.1111/all.12792.

87. Fuertes E, Markevych I, Bowatte G, et al. Residential greenness is differentially associated with childhood allergic rhinitis and aeroallergen sensitization in seven birth cohorts. Allergy. 2016;71(10):1461–1471. doi: 10.1111/all.12915.

88. Schröder PC, Illi S, Casaca VI, et al. A switch in regulatory T cells through farm exposure during immune maturation in childhood. Allergy. 2017;72(4):604–615. doi: 10.1111/all.13069.

89. Benet M, Albang R, Pinart M, et al. Integrating clinical and epidemiologic data on allergic diseases across birth cohorts: a harmonization study in the mechanisms of the development of allergy project. Am J Epidemiol. 2019;188(2):408–417. doi: 10.1093/aje/kwy242.

90. Hellings PW, Fokkens WJ, Bachert C, et al. ARIA and EPOS working groups positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis — A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297–1305. doi: 10.1111/all.13162.